32545-59-8 Usage
Uses
Used in Osteoporosis Treatment:
[1-(dimethylamino)ethylidene]bisphosphonic acid is used as a therapeutic agent for osteoporosis, a condition characterized by reduced bone mass and increased susceptibility to fractures. By slowing down the breakdown of bone and reducing the amount of calcium released into the blood, this bisphosphonate drug helps to maintain bone density and strength, thereby reducing the risk of fractures and improving the overall quality of life for patients.
Used in Paget's Disease of Bone Treatment:
In the treatment of Paget's disease of bone, a chronic disorder that causes bones to grow abnormally and weaken, [1-(dimethylamino)ethylidene]bisphosphonic acid is employed as a medication to regulate the excessive bone resorption and formation. Its ability to slow down the breakdown of bone and reduce calcium release into the blood helps to alleviate the symptoms and complications associated with this disease, such as bone pain, deformities, and an increased risk of fractures.
Used in Hypercalcemia Treatment:
[1-(dimethylamino)ethylidene]bisphosphonic acid is also used as a treatment for hypercalcemia, a condition in which there is an abnormally high level of calcium in the blood. By reducing the amount of calcium released from the bones into the bloodstream, this bisphosphonate drug helps to lower blood calcium levels and alleviate the symptoms of hypercalcemia, such as muscle weakness, fatigue, and constipation.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, [1-(dimethylamino)ethylidene]bisphosphonic acid is used as an active pharmaceutical ingredient (API) for the development of medications targeting bone-related disorders. Its unique properties and mechanism of action make it a valuable component in the formulation of drugs aimed at improving bone health and treating conditions like osteoporosis, Paget's disease of bone, and hypercalcemia.
Potential Side Effects:
While [1-(dimethylamino)ethylidene]bisphosphonic acid is an effective treatment for various bone-related disorders, it may also have potential side effects such as gastrointestinal irritation, musculoskeletal pain, and atypical femur fractures. Patients and healthcare providers should be aware of these possible side effects and monitor for any signs of adverse reactions during treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 32545-59-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,5,4 and 5 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 32545-59:
(7*3)+(6*2)+(5*5)+(4*4)+(3*5)+(2*5)+(1*9)=108
108 % 10 = 8
So 32545-59-8 is a valid CAS Registry Number.
InChI:InChI=1/C4H13NO6P2/c1-4(5(2)3,12(6,7)8)13(9,10)11/h1-3H3,(H2,6,7,8)(H2,9,10,11)
32545-59-8Relevant academic research and scientific papers
The synthesis of 1-amino-2-hydroxy- and 2-amino-1-hydroxy-substituted ethylene-1,1-bisphosphonic acids and their N-methylated derivatives
Griffiths,Hughes,Brown,Caesar,Swetnam,Cumming,Kelly
, p. 17815 - 17822 (2007/10/03)
A synthesis of 2-amino-1-hydroxyethylene-1,1-bisphosphonic acid 3 has been developed from N-phthaloylglycine via dimethyl 2-(N-phthaloylamino)acetylphosphonate 1. The preparation of the N-methylated and N,N-dimethylated derivatives 4 and 5 has been achieved by the reaction of 3 with formic acid and formaldehyde. The synthesis of 1-amino-2-hydroxyethylene-1,1-bisphosphonic acid 9 (R=R'=H) and its N-methylated and N,N-dimethylated analogues has been achieved by the reaction of phosphorus trichloride and phosphorous acid with the appropriate O-benzyl protected hydroxyacetamide, followed by catalytic hydrogenolysis of the protecting group.
